March 28, 2019
The Award is in recognition of F2G’s dedication to the development of novel therapies to treat life-threatening invasive fungal infections in an area of a high unmet medical need. In November 2018 F2G Biotech GmbH Austria received a €24M venture loan from the EIB’s InnovFin Infectious Diseases Finance Facility (IDFF). The EIB is one of the largest venture debt providers in Europe and reviews more than 2000 financing requests and conducts more than 70 due diligences per year.
